Browsing by Author "Zannoun M."

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Dysregulation of miR-125b predicts poor response to therapy in pediatric acute lymphoblastic leukemia
    (Wiley-Liss Inc., 2019) El-Khazragy N.; Elshimy A.A.; Hassan S.S.; Matbouly S.; Safwat G.; Zannoun M.; Riad R.A.; Department of Clinical Pathology and Hematology; Faculty of Medicine; Ain Shams Medical Research Institute (MASRI); Ain Shams University; Cairo; Egypt; Former Department of Biomedical Research; Armed Forces College of Medicine (AFCM); Cairo; Egypt; Department of Medical Microbiology and Immunology; Faculty of Medicine; Cairo University; New Giza University; Cairo; Egypt; Department of Clinical Pathology; National Cancer Institute; Cairo University; Cairo; Egypt; Department of Pediatrics; Faculty of Medicine; Ain Shams University; Cairo; Egypt; Department of Cancer Biology; Faculty of Biotechnology; October University for Modern Sciences and Art (MSA) University; Cairo; Egypt; Department of Pediatrics; Faculty of Medicine; Al Azhar University; Cairo; Egypt; Department of Biotechnology and Molecular Biology; Global Research Lab; Cairo; Egypt
    Background: Acute lymphoblastic leukemia (ALL) is the most well-known sort of leukemia in children. In spite of favorable survival rates, some patients relapse and achieve a poor outcome. Methods: We analyzed miR-125b and Bcl-2 expressions in pediatric patients with ALL and evaluated their clinical utility as molecular markers for the prediction of disease outcomes. Results: Downregulation of miR-125b and increased Bcl-2 expression levels in pediatric patients with ALL were associated with poor prognosis at diagnosis. At day 28 of induction, miR-125b was significantly increased, whereas Bcl-2 was downregulated. Loss of miR-125b during diagnosis and its elevation after therapy are strongly correlated with short leukemia-free survival and worse survival. Moreover, the combination of miR-125b with Bcl-2 markers can clearly enhance the prediction of the disease outcome. Finally, a univariate analysis highlighted the independent prognostic value of miR-125 in a pediatric patient with ALL. Conclusions: miR-125b and Bcl-2 together are potent predictors for the prognosis and, therefore, can be used as therapeutic targets in childhood ALL. � 2018 Wiley Periodicals, Inc.